WAVE Life Sciences Pte. Ltd. (NASDAQ:WVE) Q4 2019 Earnings Conference Call - Final Transcript

Mar 02, 2020 • 08:00 am ET


WAVE Life Sciences Pte. Ltd. (NASDAQ:WVE) Q4 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning and welcome to the Wave Life Sciences Fourth Quarter and Full-Year 2019 Conference Call. [Operator Instructions] As a reminder, this call is being recorded and webcast.

I will now turn the call over to Kate Rausch, Head of Investor Relations at Wave Life Sciences. Please go ahead.

Kate Rausch

Thank you, operator. Good morning and thank you for joining us today to discuss our recent business progress and review Wave's fourth quarter and full-year 2019 operating results. With me here today is Dr. Paul Bolno, our President and CEO; Dave Gaiero, Interim CFO; and Dr. Mike Panzara, Wave's Chief Medical Officer.

This morning, we issued a news release detailing our fourth quarter and full-year results. Please note that this news release and the slide presentation that accompanies this webcast are available in the Investors section of our website www.wavelifesciences.com.

Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2019. We undertake no obligation to update or revise any forward-looking statements for any reason.

I'd now like to turn the call over to Paul Bolno, President and CEO of Wave Life Sciences. Paul?

Paul Bolno

Thank you, Kate. Good morning and thank you for joining us today. I'll start today's call with a few introductory remarks and the Company update. Next, Dave Gaiero will discuss our financial results and then, Mike Panzara, will provide an update on our PRECISION-HD development programs. I'll conclude with an update on our ADAR-

Mediated RNA editing program and an outlook for 2020.

Wave is a genetic medicines company that was founded to design and develop novel oligonucleotide therapeutics using our proprietary PRISM platform. This unique platform enables us to design therapies in a rational way through a deep understanding of how the interplay among sequence, chemistry and stereochemistry impact key pharmacological properties. Over the past decade, our chemistry has progressed and evolved, enabling us to build a broad pipeline that includes different modalities, a range of disease targets, and innovative properties such as unique backbone modification, allele-selective designs and novel modalities like RNA editing. Going forward, we will continue to innovate and expand our pipeline. The foundation of this pipeline is our work in CNS, including Huntington's disease, ALS and FTD and several programs in collaboration with our partner, Takeda.

Over the course of our relatively short history, we've moved three programs into clinical development and have embraced and been humbled by the learnings that have come out of these and other programs along the way. Our dedicated and experienced team is actively preparing to advance two additional programs into clinical development in the second half